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Summary The expression of hepatocyte growth factor/scatter factor (HGF/SF) was studied in 12 mesothelioma cell lines characterized by
either an epithelioid or a fibroblast-like phenotype. Conditioned media from these lines were analysed by bioassay and ELISA, and HGF/SF
was detected in three cell lines, all with a fibroblast-like or mixed morphology. None of eight epithelioid cell lines expressed the factor. Thus,
for these cell lines, the ability to secrete HGF/SF correlated with the cell phenotype. Following on from these observations, two cell lines, BR
and BT, with a fibroblast-like and an epithelioid phenotype, respectively, were further investigated. Both cell lines expressed the Met receptor
but only BR secreted HGF/SF. Both cell lines responded to exogenous HGF/SF treatment by a change of morphology but in different ways:
BR became more elongated and bipolar, while BT formed more spread-out cell colonies. HGF/SF acted as a paracrine effector on the
epithelioid BT cells and stimulated both cell-spreading and proliferation. Interestingly, BT cells spread but did not scatter in response to
exogenous HGF/SF. In contrast BR cells showed only some stimulation of cell motility with HGF/SF and no increase in cell proliferation was
observed. Because HGF/SF was previously found in the pleural effusion fluids of patients with malignant mesothelioma and in paraffin-
embedded tumour tissues, it is concluded that HGF/SF may well stimulate the growth and spread of malignant mesothelioma in vivo by
paracrine and/or autocrine mechanisms.
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Malignant mesothelioma (MM) is a tumour of serosal origin asso-
ciated with previous asbestos exposure (reviews, Craighead, 1987;
Bielefeldt-Ohmann et al, 1996). It is a tumour with a long latency
period, and the incidence is currently rising in the UK (Peto et al,
1995). MM is an aggressive cancer and conventional therapies,
including surgery, irradiation and chemotherapy, are largely
unsuccessful. Because ofits refractory nature, an understanding of
the mechanisms promoting MM development and growth needs to
be obtained to provide novel avenues foralternative therapies.
In an effort to understand the mitogenic and motility factors
associated with MM, the expression and regulation of a variety of
cytokines, growth factors and their receptors have been studied
both in vivo and using mesothelioma cell lines (reviews
Fitzpatrick et al, 1995; Bielefeldt-Ohmann et al, 1996). It has been
reported that human mesothelioma cell lines (HMCLs) express a
variety of factors, including platelet-derived growth factor A and
B (Gerwin et al, 1987; Versnel et al, 1988; Galepp et al, 1993),
insulin-like growth factor I (Lee et al, 1993), transforming growth
factor-: and fibroblast growth factor-2 (Asplund et al, 1993). All
ofthese factors have the potential to stimulate MM growth.
Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunc-
tional protein with varied effects. It is synthesized as a single-chain
inactive precursor peptide that is cleaved after secretion into an a,B
heterodimer (Miyazawa et al, 1989; Nakamura et al, 1989). The
cleavage step is required for biological activity and occurs outside
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the cell after secretion (Gak etal, 1992; Naldini etal, 1992). At least
twoproteins are known that arecapable ofcleaving the precursor, a
serine proteinase HGF/SF activator (Miyazawa et al, 1993) and
urokinase-typeplasminogen activator(Naldini etal, 1992). HGF/SF
acts as a strong mitogenic, motogenic and morphogenic agent and
has been shown both in vivo and in vitro to have the remarkable
capacity to rupture cell-celljunctions of a widevariety ofepithelial
cell types (reviews, Gherardi et al, 1993; Rosen et al, 1994).
Because of its varied biological properties, the expression of
HGF/SF in tumours may well act to enhance cellgrowth andspread
and to stimulate metastasis. An increasing number of reports have
recorded that both HGF/SF and its receptor, Met, areexpressed, and
often overexpressed, in various cancers, such as bladder, lung,
pancreas, thyroid, colon and stomach carcinoma (Di Renzo et al,
1991,1995; Prat etal, 1991; Natali etal, 1993;Joseph etal, 1995). In
breast cancer, the level ofHGF/SF associated with tumour material
has been reported to be a strong indicator of recurrence and
predictorofsurvival (Yamashita etal, 1994).
More definitive evidence for the role of HGF/SF in tumori-
genesis has emerged through the use of transfected murine NIH
3T3 fibroblasts: coexpression of human Met receptor and its
ligand in NIH 3T3 cells causes the cells to become tumorigenic in
nude mice (Rong et al, 1992). The resultant tumour cells coex-
pressed epithelial and mesenchymal markers, suggesting a mesen-
chymal to epithelial conversion (Tsarfaty et al, 1994). Thus, the
Met-HGF/SF signalling pathway could play a role in mesen-
chymal tumours, such as MM, that express both epithelial and
mesenchymal markers.
In a previous study, it was found that pleural effusion fluids
from over 90% of patients with MM or primary lung cancers
contained biologically significant amounts of HGF/SF as judged
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by ELISA and 'scattering' bioassay (Eagles et al, 1996).
Immunohistochemical staining for HGF/SF has also been
observed in histological sections from -75% ofpatients with non-
small-cell lung carcinomas and in all MMs examined (Harvey et
al, 1996). Study ofthe Met receptor using immunohistochemistry
also showed that it was present in cells from all the lung cancers
and malignant mesotheliomas. However, such immunoreactivity
for HGF/SF does not necessarily imply that it was secreted by the
tumourcells oracts on them. To study this more directly, the secre-
tion of HGF/SF has been assessed in tissue culture supernatants
obtained from 12 well-characterized human mesothelioma cell
lines (HMCLs). The presence ofHGF/SF and Met and the effects
of exogenous HGF/SF have been further investigated using two
cell lines: BR, a mesothelioma cell line with a fibroblastic pheno-
type, and BT, which has an epithelioid morphology.
MATERIALS AND METHODS
Cell culture and conditioned medium preparation
Twelve cell lines obtained from patients with malignant mesothe-
lioma were routinely grown in RPMI-1640 with 10% fetal calf
serum (FCS) (Gibco, BRL) as previously described (Zeng et al,
1994). These cell lines have all been carefully characterized as
being derived from mesotheliomas, using a panel of antibody
markers. All ofthem were both cytokeratin and vimentin positive
and CEA negative (Zeng et al, 1994). For the production ofcondi-
tioned medium, confluent cells were washed with phosphate-
buffered saline (PBS) and further cultured in serum-free medium
for 24 h. The cells were then incubated in fresh serum-free
medium for another 48 h. This medium was then collected, clari-
fied and stored at - 700C,
Scattering bioassay and ELISA
The presence ofHGF/SF was testedby scattering bioassay as previ-
ously published (Stoker and Perryman, 1985) using conditioned
medium obtained from the 12 mesothelioma cell lines. The condi-
tioned media were then tested for HGF/SF using an enzyme-linked
immunosorbent assay (ELISA) kit (Diagnostic Division, Otsuka
Pharmaceutical, Tokushima, Japan) originally described by
Table 1 Detection of HGF/SF in HMCL conditioned media
Cell line Origin Bioassay ELISA Morphology
BR PE + + (1 ng ml-') F
TA PL + + (0.2 ng ml-') M
D PE + + (2.0ngml-') M
H PL - - F
BT PE - - E
o PE - - E
R PE - - E
ME PL - - E
TI PL - - E
MRc PL - - E
BL PL - - E
P PL - - E
The data shown for ELISA were from neat conditioned medium and were
further checked using 20-fold concentrated medium (not shown). F,
fibroblast-like; E, epithelioid; M, mixed. PE, pleural effusion; PL, pleural
aspirate or tumour material after resection.
Tsubouchi et al (1991). The detection limit ofthe test is 0.2 ngml,-'
and it is highly specific for cleaved, active, heterodimeric human
HGF/SF. It does not cross-react with the precursor single-chain
form ofHGF/SF(Arakaki etal, 1995). Both neatandapproximately
x 20 concentrated samples were examined using ELISA. This was
to determine whether any lines secreted very small amounts of
HGF/SF, below the level that produces effects in the scattering
bioassay. Sample concentration was performed using Centricon
tubes (Amicon), with a molecularweight cut-offof 10 kDa.
Immunostaining for HGF/SF and Met
For HGF/SF immunostaining, the factor was first concentrated
within the Golgi following the method of Hembry et al (1986).
Cells were initially seeded on round 1-cm diameter coverslips.
After 24 h in culture, 5 gM monensin (Sigma) was added to the
cells for 4 h and the cells were then fixed for 20 min in 4% (w/v)
paraformaldehyde at 25°C. They were then permeabilized in a
buffer containing 0.1 mm calcium chloride, 1 mm magnesium
chloride, 0.2% (w/v) Triton X-100, pH 7.3, for 5 min. The cells
were washed three times with PBS, which was repeated between
each of the following steps. All the incubations were carried out
for 1 h at 37°C. Non-specific binding sites were first blocked by
treatment with 10% rabbit serum in PBS followed by treatment
with a 1:800 dilution of a goat anti-human polyclonal HGF/SF
antibody (R & D Systems, Abingdon, UK) and then incubation
with a 1:600 dilution of a rabbit anti-goat FITC-conjugated anti-
body (Dako, High Wycombe, UK). For Met immunostaining, the
cells were fixed as before but not permeabilized. Cells were incu-
bated first with antibodies against the extracellular domain of
human Met (mouse monoclonal DO-24; Prat et al, 1991; Upstate
Biotechnology, New York, USA) and then with a 1:40 dilution of
anti-mouse rhodamine-conjugated antibodies (Dako). Finally, the
coverslips were mounted on slides using Citifluor (Citifluor,
London) as an anti-fade mountant and observed using epifluores-
cence optics with a Zeiss Standard microscope. Photographs were
taken using T-MAX 400 film.
RNA extraction
Total RNA was extracted from subconfluent cultures of BT and
BR cells grown in 10 cm diameter Petri dishes following the
guanidinium thiocyanate method (Chomczynski and Sacchi,
1987). RNA samples were resuspended in dimethyl pyrocarbonate
(Sigma)-treated water and the concentration and purity assessed
by measuring absorbance at 260 and 280 nm.
Reverse transcription polymerase chain reaction
(RT-PCR) for HGF/SF and Met
The cDNA sequences of human HGF/SF and Met were retrieved
from the GenBank database; accession numbers were M29145 for
HGF/SF and J02958 for Met. For the detection of each mRNA,
three specific primers were designed. One reverse primer 150-
200 bp downstream to the PCR fragment was used for the RT and
the following primers for the PCR amplification.
HGF/SF: sense; 5'-GGGGAGAGTTATCGAGGTCTC-3',
anti-sense; 5'-GGTCCATGAGCATCATCATCT-3',
Met: sense; 5'-CAGGTGCAAAGCTGCCAGTGAAGT-3',
anti-sense; 5'-GCACTATGATGTCTCCCAGAAGGA-3'.
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With these primers, the amplimers for HGF/SF and Met were
703-bp (nucleotides 747-1450) and454-bp fragments (nucleotides
3970-4424) respectively.
RT-PCR was carried out using a Hybaid Amplifier. Equal
amounts of total RNA (5 jig) were used as templates for cDNA
synthesis. To the RNA, 4 ng of the specific downstream primer
and 0.5 gl of RNAguard (Pharmacia) were added and heated at
65°C for 15 min, then quickly cooled on ice. A mix solution
containing 2 gl of 5 x buffer (Gibco BRL), 1 gl of Superscript
reverse transcriptase (Gibco BRL) and 0.5 ,ul of dNTP (Gibco
BRL) was added to each tube, to a final volume of 10 ,l. The RT
was performed at 42°C for 1 h, and an aliquot of the RT reaction
was then used to perform hot-start PCR. A final volume of 40 ,l
for the PCR reaction contained: 0.5 pl of 10 mm dNTP, 4gl of
10 x buffer (Gibco BRL), 8 ng ofeach sense and anti-sense appro-
priate primers. The reaction mix was heated at 94°C before the
addition of 0.5 gl of Taq DNA polymerase (Gibco BRL), and the
amplification reaction was carried out over 35 cycles with
the following parameters: step 1, 94°C for 45 s; step 2, 60°C for
1 min; step 3, 72°C for 1 min. For the final cycle, the 72°C step
was extended to 10 min to obtain full-length PCR products. A
quarter ofthe PCR products were then loaded on 1% agarose gels
and stained with ethidium bromide.
Western blot analysis of Met
Protein extraction and Western blots were carried out as described
in Webb et al (1996). Equal amounts of proteins (20 jg) per lane
were loaded and separated on 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose
membrane (ECL-Hybond, Amersham). Blots were probed with
anti-human Met protein antibodies (C28, Santa Cruz) and with
HRP-conjugated goat anti-rabbit immunoglobulins (Sigma).
Phosphotyrosine-containing proteins were detected with anti-
phosphotyrosine-HRP (RC20, Transduction Laboratories).
Detection was carried out using the enhanced chemiluminescence
system (Amersham).
Scratch wound motility assay
HMCLs were grown in 24-well tissue culture plates (Falcon) to
confluence. The monolayers were then carefully scratch wounded
with sterile Gilson pipette tips. The cells were cultured with or
without 10% FCS and exposed for 24 h to human recombinant
HGF/SF (10 ng ml-') (Harvey et al, 1996). The cells were then fixed
in 4% formaldehyde in 0.9% saline and stained with Loeffler stain.
The experiments were repeated in quadruplicate three times and
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Figure 1 RT-PCR amplification of HGF/SF and Met mRNAs in BR and BT
cells. Lane 1, 1-kb DNA ladder; lane 2, placenta control; lane 3, placenta
control without RT; lane 4, BT cell line; lane 5, BR cell line. Amplimers are
703 bp for HGF/SF and 454 bp for Met
representative fields photographed. Scratches had an original width
of 1.40 mm. Cells were observed with a Nikon inverted-phase
microscope andphotographs taken using T-MAX 400 film (Kodak).
Proliferation assay
Assay of DNA synthesis by the two cell lines was performed
in quadruplicates as described in Duncan et al, (1996).
Approximately 2 x 104 cells were cultured in 24-well plates. When
50-60% confluent, the cells were supplemented with a range of
FCS concentrations and with or without HGF/SF (10 ng ml-') for
24 h. During the last 4 h ofculture, the cells were pulsed with cold
thymidine (1 gM) and [3H]thymidine (1 gCi ml-' (Amersham).
The experiments were terminated by washing the cells twice with
PBS before fixing them with 5% TCA for 30 min at 4°C. One
millilitre of sodium hydroxide (250 mM) was added to each well
and left overnight to extract the tritium incorporated into the DNA.
Of this solution, 0.5 ml was added to 10 ml of scintillation fluid
(Picofluor 15) to be counted in a Packard scintillation counter. The
results were expressed as d.p.m. per well and statistically analysed
using the t-test (P < 0.05). The experiments were repeated three
times.
RESULTS
Secretion of HGF/SF by human mesothelioma cell lines
The secretion of HGF/SF protein by HMCLs was analysed by
bioassay and ELISA in serum-free conditioned medium. Three out
of 12 HMCLs secreted HGF/SF (Table 1). Of these, three out of
four cell lines with a fibroblast-like or mixed morphology secreted
HGF/SF, while none ofthe eight cell lines with an epithelial mode
ofgrowth did so. The levels ofHGF/SF found in the tissue culture
supernatants varied significantly as judged by ELISA, but in all
three cases the tissue culture medium also gave a clear-cut positive
in the bioassay. However, the fourth fibroblast-like cell line was
negative both for the ELISA and for the bio-assay. Overall, the
results suggest a relationship between the morphology of the cell
lines and their ability to express HGF/SF. Therefore, it was
decided to investigate further two representative cell lines, one
with an obvious fibroblast-like morphology, BR, which secretes
HGF/SF, and one with a clearly defined epithelioid form, BT,
which does not.
Expression of HGF/SF and Met in BT and BR cell lines
As shown by RT-PCR amplification, both BR and BT HMCLs
expressed high levels of Met mRNA, but only BR expressed
HGF/SF mRNA (Figure 1). Total RNA extracted from term
placenta was used as a positive control, and all RT-PCR amplifica-
tions were repeated from three separate RNA extractions. The
primer specificity was previously checked on plasmids containing
the HGF/SF and Met cDNA or irrelevant inserts (data not shown).
In addition, the HGF/SF PCR product was cleaved in the middle
using the EcoRI restriction enzyme to check its identity and to
distinguish it from an unlikely but possible MSP/HGF-like growth
factor amplimer (data not shown); this growth factor is from the
same family as HGF/SF and has regions of high homology in its
DNA sequence (Han et al, 1991; Yoshimura et al, 1993). In addi-
tion, the NK2 variant of HGF/SF was not detected in BT or BR
cells by RT-PCR (data not shown).
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Figure 2 Western blot analysis of Met protein from BR and BT cells. After
overnight serum starvation, HGF/SF increased the phosphorylation of Met
receptor (145-kDa 13-chain). Numbers above the gel indicate the time course
in min
Tyrosine phosphorylation of Met
Both BT and BR cells synthesize Met protein, as judged by the
presence of a band at 145 kDa in Western blots using the antibody
C-28, which corresponds to the Met f-chain (Prat et al, 1991)
(Figure 2). Probing of duplicate blots with a specific antibody
against phosphotyrosine demonstrated an increase in the tyrosine
phosphorylation of the 145-kDa Met subunit after a 10-min treat-
ment with HGF/SF (10 ng ml-') for extracts from both BR and BT
cells and this increased furtherby 20 min, demonstrating activation
of the receptor by its ligand (Figure 2). A number of other bands
showed increases in phosphorylation on tyrosine for both cell lines
after the addition ofHGF/SF, but these were not studied further.
Immunofluorescence localization of HGF/SF and Met
The presence of HGF/SF and Met were also investigated using
immunofluorescence. After monensin treatment, bright fluorescent
masses containing granular and tubular material were present adja-
cent to the nuclei in BR but not BT cells (Figures 3A and B). This
very likely represents accumulation of HGF/SF within the Golgi
apparatus, allowing its visualization within the cells. Immuno-
staining for Met of the surfaces of both BR and BT cells showed a
pattern of dot-like aggregates over the cell plasma membranes
(Figures 3C and D). The patterns of staining seen for Met were
similar for both cell lines and markedly resembled the Met aggre-
gates previously described in the plasma membranes of MDCK
cells (Webb et al, 1996). Controls lacking the primary antibodies
showed no specific immunostaining, only faint background
staining similar to that seen in Figure 3B (not shown).
Cell motility and morphology changes after the
addition of HGF/SF
BT cells showed atypical epithelioid morphology and formed well-
defined colonies in culture. When confluent, they demonstrated a
typical 'cobblestone' pattern (Figure 4A). In scratch wounds of
confluent cultures, HGF/SF markedly stimulated the flattening and
spread ofBTcells along the edges ofthe wound, compared with the
controls (Figure 4B). When viewed at higher power, the increased
spreading ofthe cells close to the wound due to HGF/SF was more
evident (compare Figure 4D with 4C). Interestingly, HGF/SF did
not induce scattering of these cells but only enhanced spreading
with the cells moving as contiguous sheets.
BR cells showed a typical fibroblast-like morphology, often
with a bipolar shape. However, they frequently demonstrated
cell-cell contacts (Figure 5A). When treated with HGF/SF for
24 h, the cells clearly showed enhanced movement into the scratch
Figure 3 Immunofluorescence detection of HGF/SF (A and B) and Met (C and D) in BR cells (A and C) and BT cells (B and D). Notice the immunostaining of
HGF/SF in the Golgi of BR cells treated with monensin (A). Bar = 25 ,um
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Figure 4 Scratch wounds of confluent BT cultures after 24 h. A and C, controls; B and D, 10 ng ml-' HGF/SF. The low-powerimages (A and B) are the same
magnification, as are C and D, which are higher power. Bars = 400gm. Dashed lines indicate the original boundaries of the scratches in A and B
C _" 0
.. . .
Figure 5 Scratch wounds of confluent BR cultures after 24 h. A and C, controls; B and D, 10 ng ml- HGF/SF. The low-power images (A and B) are the same
magnification, as are C and D, which are higher power, Bars = 400 im. Dashed lines indicate the original boundaries of the scratches in A and B
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Figure 6 Effects of 10 ng ml-' HGF/SF on the proliferation of the BT (A) and
BR (B) cells in serum-free medium (O) or serum-stimulated conditions (U)
(1% and 5% FCS). Comparing the data for control and HGF/SF treated cells,
the results were significantly different only for BT using the t-test (*P < 0.05).
The results are expressed as means + s.e.m. (bars)
wounds (Figure SB), compared with controls (Figure SA). At
higher power, it is apparent that the cells, particularly at the wound
edge, were somewhat more dispersed and had longer processes
when treated with HGF/SF (compare Figures 5C and D).
These results were obtained with cells growing in 10% FCS.
When BR and BT cells were grown in serum-free medium,
HGF/SF treatment had a much reduced effect on cell motility.
HGF/SF and HMCL proliferation
As shown inFigure6, theproliferation ofboth cell lines was stim-
ulatedby the presence of serum. BT cell proliferation was signifi-
cantly increased by -35% within 24 h of HGF/SF treatment, but
only in the presence of serum. In contrast, BR mitogenesis showed
no overall change after the addition of HGF/SF.
DISCUSSION
We previously found that pleural effusions from patients with
MM contained high levels of HGF/SF (Eagles et al, 1996).
Furthermore, we observed that sections of MM showed clearly
observableimmunostaining both for HGF/SF and for Met receptor
(Harvey et al, 1996). The data from the mesothelioma cell lines
demonstrate that the HGF/SF, at least in part, very likely originates
from the tumour cells themselves. Our previous data showed
immunohistochemical staining of essentially all the tumour cells
in both the epithelioid and the sarcomatoid forms of malignant
mesothelioma. In contrast, the data from cell lines so far suggest
thatonly those of sarcomatoid or mixed type secrete HGF/SF. It is
conceivable that the epithelial cell lines stopped expressing
HGF/SF in vitro, and that they might express HGF/SF in situ after
receiving some additional stimulation from extracellular signals.
An alternative explanation is that HGF/SF immunoreactivity was
detected in cells that took up HGF/SF or trapped the factor on the
cell surface. On close examination, many epithelial-type tumours
contain mixed areas and the morphologies are highly variable
(Hillerdal, 1983). In any case, it is very likely that all types ofMM
are exposed to significant amounts of HGF/SF in situ, as we also
found HGF/SF immunoreactivity in the extracellular matrix asso-
ciated with the tumour and in subserosal mesenchymal cells
(Harvey et al, 1996). The results from the BR and BT cell lines
suggest that HGF/SF has both mitogenic and motility-inducing
effects on mesothelioma cells, which could drive tumour growth
and spread. These effects may occur via either autocrine or
paracrine mechanisms. Furthermore, because in both BR and BT
basal levels of phosphorylation of Met was seen in controls, it is
possible that constitutive activation ofMet may also occur.
Three out of four cell lines showing a sarcomatoid phenotype
were found to secrete HGF/SF, while none ofthose with an epithe-
lioid phenotype did so. Thus the secretion ofHGF/SF seems to be
associated with the sarcomatoid phenotype. It is more likely to be
a consequence rather than a cause ofthe cell type because one line
with a fibroblast-like phenotype did not secrete the factor. Stoker
et al (1987) originally found that fibroblasts of various origins
secreted HGF/SF and that epithelial cells of various types
responded to the factor, i.e. HGF/SF acts via a paracrine mecha-
nism of action. More generally, in early development, coexpres-
sion ofthe HGF/SF and c-Met genes precedes separate expression
in adjacent tissues, which occurs as organogenesis proceeds
(Sonnenberg et al, 1993; Woolf et al, 1995; Andermacher et al,
1996). Therefore the sarcomatoid mesothelioma cell lines may
reflect a more primitive mesenchymal developmental state.
There is limited but increasing evidence that coexpression of
HGF/SF and its receptor, Met, may occur during tumorigenesis.
Rong et al (1993) demonstrated that a variety of sarcoma cell lines
secrete HGF/SF and also express Met. Two of these lines also
showed an increased mitogenic response to exogenous HGF/SF
Furthermore, transfection of human Met and HGF/SF genes into
3T3 cells results in cell lines highly tumorigenic in nude mice, as a
result of autocrine stimulatory mechanisms (Rong et al, 1992).
Mesangial fibroblasts also both secrete HGF/SF and synthesize Met
(Kolatsi-Joannou et al, 1995). The addition of HGF/SF causes an
increase in thebipolarmorphology ofmesangial cells, suggesting an
autocrine role of HGF/SF in maintaining fibroblast morphology.
Our results with the BR line are in general accord: the cells secrete
HGF/SF and respond to exogenous HGF/SF by some increase in
cell motility associated with a more bipolar morphology. However,
for this cell line, mitogenic effects due to HGF/SF were not found.
The results for BT, as a clearly obvious epithelioid-type mesothe-
lioma line, fit more closely with what is known for many epithelial
cell types. HGF/SF is not secreted but the cells respond to it by
increased cell division rates and also by enhanced cell-spreading.
Rather surprisingly, although BT cells showed increased spreading,
they did not scatter in response to HGF/SE Stoker and Penryman
(1985) demonstrated that MDCK cells initially spread in response to
HGF/SF and then ruptured the cell-cell junctions leading to colony
dispersion. Dowrick et al (1991) found aroughly twofold increase in
the mean projected areas of MDCK cells as they spread out after
HGF/SF treatment but none at all in PtK2 cells, so not all cell types
respond in this fashion. The reason why cell-cell junctions are not
ruptured by HGF/SF in the BT line is not yet known.
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Malignant mesotheliomas show a diversity of morphologies
with three main histological types being recognized: epithelioid,
sarcomatoid and mixed (Hillerdal, 1983). The epithelioid form is
most common but the percentage ofmixed tumours increases after
careful sampling (van Gelder et al, 1991). Cell lines with a sarco-
matoid cell type can be obtained from epithelioid mesotheliomas
(Fleury-Feith et al, 1995) and vice versa (Alvarez-Fernandez and
Diez-Nau, 1979). There are two possible explanations for the
extreme pleiotropism of morphology frequently encountered in
MM. Either the two cell morphologies can interconvert, or the
epithelial and fibroblast-like forms are derived from different cell
types (review, Craighead, 1987). The mesothelial serosal layers of
the coelomic cavities have generally been considered to be one
origin of malignant mesotheliomas. Detailed examination of the
epithelial form of the disease seems to support this hypothesis
because the malignant cells frequently show a marked similarity of
structure to normal mesothelial cells. However, an origin ofmalig-
nant mesothelioma from the underlying fibroblast layer cannot be
excluded. Davis (1979) found that premalignant transformational
changes occurred in the submesothelial fibroblast layer of
asbestos-injected rats before the development of mesothelioma
and MM may arise in this layer. Examination of mesotheliomas
often demonstrates the presence of a seemingly normal mesothe-
lium layer overlying the tumour (Craighead, 1987). Furthermore,
even the origin of the cell population that renews the mesothelium
is unclear (see Whitaker et al, 1982), and so both the possible
origins of MM must be considered when reviewing the very
different characteristics ofthe BR and BT lines.
In conclusion, HGF/SF becomes a further growth factor that is
probably involved in the development of MM, and it is one with
particular features. The ability to synthesize HGF/SF and also the
kind of response induced by the addition of the factor correlate
well with the cell morphology. Whether or not the different pheno-
types reflect the tissue oforigin ofthe tumour or are aconsequence
of an intrinsic multipotentiality of mesothelial cells has still to be
determined. How far the secretion of HGF/SF may be associated
with the sarcomatoid form of mesothelioma remains to be deter-
mined. The median survival time, from first symptoms, for the
sarcomatoid form of mesothelioma has been recorded to be
approximately halfthat ofthe epithelial and mixed types (5, 11 and
10 months respectively) in a large sample of patients (Hillerdal,
1982). The sarcomatoid form of mesothelioma is therefore the
more aggressive form with a shorter life expectancy. It will be of
interest to determine what associations HGF/SF may have with
tumour type in vivo, not least for the development of future
strategies for therapy.
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